NetworkNewsBreaks – Foamix Pharmaceuticals (NASDAQ: FOMX) Shares Sink on Report of Topline Results from Phase 3 Trials for FMX101

Shares of Foamix Pharmaceuticals (NASDAQ: FOMX) dove 50% this morning following the company’s report of topline results from its two phase 3 clinical trials investigating FMX101 (Trial 04 and Trial 05) in patients with moderate-to-severe acne. The two co-primary endpoints were the absolute change in the number of inflammatory lesions (papules and pustules); and the proportion of patients achieving success at week 12, as defined by an Investigator’s Global Assessment (IGA) score of “clear” or “almost clear” and at least a two-grade improvement from baseline at week 12. FMX101 did not demonstrate statistical significance of IGA success in Trial 04. However, in the intent-to-treat analysis, FMX101 demonstrated statistical significance compared to vehicle on both co-primary endpoints in Trial 05. “Our team has not yet received the full data set and we intend to provide an update on the program as soon as we complete our analysis.  As we have previously announced, the safety extensions for trials 04 and 05 are fully enrolled and continue as planned,” CEO Dov Tamarkin, Ph.D., stated in the news release.

To view the full press release, visit:

About Foamix Pharmaceuticals

Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. The company’s clinical stage product candidates include FMX101, a novel minocycline foam for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea, FMX102 for the treatment of impetigo, and FDX104, a doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs. In addition, Foamix has development and license agreements relating to its technology with various pharmaceutical companies including Bayer HealthCare and others. For more information, please visit

About NetworkNewsBreak

NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s